PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 19, 2026Journal of Ophthalmological Society of West BengalOpen Access

Biosimilars in Retinal Disorders: Cost Revolution or Clinical Trade-off in the Indian Scenario?

View Full Paper
Ask AI
Bookmark
Share

Authors

SPS.D. Paul

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates the efficacy and safety of biosimilars in retinal disorders, suggesting significant benefits for patients in India.

Key Points

  • This research aims to assess the efficacy and safety of biosimilars in treating retinal diseases within the Indian healthcare context.
  • Evaluated biosimilar ranibizumab (Ranieyes) across multiple retinal conditions including DME, neovascularization, and RVO.
  • Utilized real-world data from the BRESER study and the ROSE Korea study to compare outcomes against reference biologics.
  • Focused on patient adherence, treatment costs, and adverse event rates.
  • Patients treated with biosimilar ranibizumab experienced significant visual improvements, notably in DME cases from 6/36 to 6/15.
  • Real-world data demonstrated comparable treatment outcomes and adverse event rates to innovator therapies.
  • Biosimilars showed a cost reduction of 50%-60%, enhancing access to treatment for more patients.

Cite This Study

S.D. Paul (2025) studied this question.

synapsesocial.com/papers/6a34def565a5b0777af2e3c6https://doi.org/10.4103/josb.josb_8_26
View Full Paper
Ask AI
Bookmark
Share